("CanSinoBio" or the "Company") has recently initiated a Phase I clinical trial of its recombinant polio vaccine in Australia and has completed the enrollment of the first subject. The Company has completed the clinical trial filing with the Therapeutic Goods Administration (TGA) under the Department of Health of Australia, and the vaccine has received ethical approval for the clinical trial from the Australian Human Research Ethics Committee prior to the filing of the clinical trial protocol.

The Company's virus-like particle (VLP)-based recombinant polio vaccine, which is based on the Company's protein structure design and VLP assembly technology, is expected to contribute to the global control and eradication of polio. The recombinant polio vaccine is a non-infectious polio vaccine that does not rely on live viruses in the production process and is expected to have good safety and immunogenicity. Unlike the marketed attenuated and inactivated polio vaccines, the non-infectious VLP polio vaccine has been recommended by the World Health Organization (WHO) as one of the vaccines of choice for future polio eradication.

http://www.cninfo.com.cn/new/disclosure/detail?stockCode=688185&announcementId=1218889846&orgId=9900038913&announcementTime=2024-01-16